Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

The dispute dates to 2013 when Apple sought Masimo’s technology to install pulse oximetry on its watch. Email correspondence ...

Apple is fighting a running legal battle with the health tech company Masimo over pulse oximetry technology and smartwatch design patents. A jury in a federal trial awarded Apple a paltry $250 ...

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

which started with the Masimo’s claim that its patents had been infringed by the Apple Watch’s pulse-oximetry feature, which allows Watch owners to measure their blood oxygen levels.

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Apple and Masimo are back in a California court this week for a bench ... the two companies in which the former alleges the ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...